کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2402629 | 1102827 | 2012 | 8 صفحه PDF | دانلود رایگان |
Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1%, the incremental cost-effectiveness ratio (ICER) of vaccination was ≤$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10% colonization prevalence, a 25% efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs ≤ $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine.
► We modeled the potential economic value of a Staphylococcus aureus vaccine in hemodialysis patients.
► Sensitivity analysis varied colonization prevalence and vaccine characteristics.
► Vaccination was cost-effective for all tested scenarios and quickly became economically dominant.
► Vaccination would be cost-effective over a wide range of prevalence rates and vaccine costs, efficacies, and protection durations.
Journal: Vaccine - Volume 30, Issue 24, 21 May 2012, Pages 3675–3682